Thyroid Eye Disease (TED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Thyroid eye disease (TED) is a rare, debilitating autoimmune disease known as Graves' orbitopathy or thyroid-associated ophthalmopathy. After 1 to 3 years, the disease progresses from an active progressive period marked by inflammation to a stable and fibrotic period. It affects approximately 40% of Graves' disease patients. In Graves' disease, autoantibodies (thyroid-stimulating immunoglobulin) targeting the thyrotropin receptor cause hyperthyroidism. The insulin-like growth factor I receptor (IGF-IR), which is overexpressed by orbital fibroblasts and B and T cells, plays a critical role in Graves' illness and thyroid eye disease. Thyrotropin receptors and IGF-IRs form physical and functional complexes that cause hyaluronan accumulation and cytokine production, resulting in inflammation, edema, and enlargement of extraocular muscle and adipose tissue.
·
The incidence of Thyroid eye disease in the
USA is 15 to 20 cases per 100,000 population in the USA.
Thelansis’s
“Thyroid Eye Disease (TED) Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Thyroid
Eye Disease (TED) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Thyroid Eye Disease
(TED) across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Thyroid
Eye Disease (TED) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Thyroid
Eye Disease (TED), Thyroid Eye Disease (TED) market
outlook, Thyroid Eye Disease (TED) competitive
landscape, Thyroid Eye Disease (TED) market
forecast, Thelansis, Primary market research, KOL insights, Competitive
Intelligence (CI)

Comments
Post a Comment